Author: miracellPH

Miracell Hosts CGP Academy on Autologous Bone Transplantation and Bone Marrow Concentration Techniques

Miracell hosts CGP Academy on “Autologous Bone Transplantation and Bone Marrow Concentration Techniques”Orthopedic surgeon Dr. Chan-il Jeong will present, explaining treatment and surgical techniques. Stem cell specialist Miracell announced on the 24th that it held a Global Platform (CGP) Academy on the topic of “Autologous Bone Transplantation and Bone Marrow Concentration Techniques.” The lecture was delivered by Dr. Chan-il Jeong, an orthopedic surgeon and director of Cellpia Clinic, a leading stem cell education institution, who personally explained actual treatment and surgical techniques to medical staff from CGP member hospitals and clinics. The lecture covered pelvic anatomy, bone marrow collection methods, and the resulting differences in outcomes. Following the lecture, Dr. Jeong vividly demonstrated the bone marrow stem cell extraction process from an actual patient in the operating room, after prior consent had been obtained. Based on the lecture, he explained the essentials and details, addressing any questions the attending medical staff had. The bone marrow stem cells were concentrated and isolated using Miracell’s “SMART M-CELL2”BmSC, a dedicated bone marrow stem cell kit certified as a new health technology by the Ministry of Health and Welfare. SMART M-CELL2 is a system that extracts large quantities of stem cells by centrifuging bone marrow blood. It is currently used by major hospitals across various medical specialties. Director Jeong emphasized, “The key is to extract stem cells easily and safely using a special trocar through a posterior approach, without side effects such as pain, bleeding, or nerve damage.” He added, “In particular, the instrument must be inserted while avoiding the iliolumbar ligament and the superior gluteal cutaneous nerve. During the procedure in the prone position, it is important to determine whether the ilium is displaced posteroinferiorly or anterosuperiorly, and to check the needle’s internal and external rotational displacement to accurately target the target point.” This bone marrow extraction technique training attracted significant interest from doctors at CGP member hospitals and clinics from the application stage, with more medical staff participating than the actual number of applicants. Unlike blood, bone marrow extraction requires a high level of technical expertise, and the amount of stem cells that can be extracted varies depending on the extraction method. Miracell’s CGP Amatemi is a platform for sharing stem cell medical technology and knowledge through an organic network with various member hospitals and clinics. Launched in 2019, Miracell Inc. strives to lead the way in specialized stem cell treatment and research, and contribute to disease treatment. It actively engages in education on a variety of topics with hospital and clinic staff. CGP provides education, technology transfer, medical equipment setup, and marketing services to hospitals both domestically and internationally, to ensure safer stem cell regenerative medicine treatments. By Sangjun Ahn

[2021 Korea New Growth Management Awards] Miracell Receives Prime Minister’s Commendation

[2021 Korea New Growth Management Awards] Miracell Receives Prime Minister’s Commendation Miracell, which domestically developed stem cell extraction equipment, won the Prime Minister’s Award at the 18th Korea New Growth Management Awards. The Korea New Growth Management Awards, jointly hosted by MBN, Maeil Business Newspaper, and the Ministry of Trade, Industry and Energy, recognize creative and innovative companies that will lead the Fourth Industrial Revolution. Miracell was recognized for its technological achievements, successfully developing and localizing the Smart Mcell 2 stem cell extraction equipment and kit. Miracell CEO Shin Hyun-soon stated, “The Smart Mcell 2 stem cell extraction equipment offers world-class cell viability and recovery rates, and is highly effective in improving bodily functions. We will lead the popularization of stem cells.” ▶See original article

Miracell Stem Cell ‘Smart Mcell 2’ Participates in Germany’s Medica

Miracell Stem Cell ‘Smart Mcell 2’ Participates in Germany’s Medica Stem cell specialist Miracell announced on the 29th that it participated in Germany’s “MEDICA 2021,” the world’s largest medical device exhibition. “MEDICA 2021” was held from November 15th to 18th at the Düsseldorf International Exhibition Center in Germany. Over 3,500 companies from 150 countries participated and 46,000 visitors attended. Miracell showcased its “state-of-the-art bio-stem cell extraction system,” developed using domestic technology. The SMART M-CELL2 is a “bone marrow and blood stem cell extraction device with a cell separation vessel capable of selective separation.” It is a cutting-edge bio-regenerative medical device that concentrates bone marrow and blood through cell separation and automatic separation to extract large quantities of isolated stem cells. Miracell CEO Shin Hyun-soon explained, “At this exhibition, Miracell’s stem cell treatment videos and pre- and post-treatment data garnered attention from international buyers. Questions poured in about stem cell extraction and treatment using SmartMcell2, as well as its effectiveness, and we secured contracts from European buyers.” He continued, “European countries like Germany, the UK, and France were particularly interested in post-COVID-19 medical devices and ‘immuno-healthcare,’ and this was a great opportunity to widely promote the benefits of stem cells through Miracell’s unique technology.” “We demonstrated to buyers the results of our treatment of skin diseases, including rare and intractable psoriasis, and introduced Miracell’s bio-stem cell system, which has received all five European CE certifications.” Miracell’s SmartMcell2 is currently undergoing global patent applications in over 40 countries, including the US Food and Drug Administration (FDA). The company is currently preparing for the 2022 Arab Health Fair in Dubai. Meanwhile, Miracell, through its membership in the Cellpia Global Platform (CGP), has built an organic network with doctors and medical staff at hospitals and clinics both domestically and internationally, sharing its specialized stem cell medical technology. CGP provides education, technology transfer, medical system setup, and marketing services to ensure safe stem cell regenerative medicine treatments for hospitals both domestically and internationally. By Jeong Myeong-jin (pompom@fnnews.com)

Miracell to Invest 3 Billion Won to Build a Production Plant in the Hwasun Vaccine Industrial Complex

Stem cell specialist Miracell Co., Ltd. to invest KRW 3 billion to build a production facility in the Hwasun Vaccine Industrial Complex. -The only bio company to participate in DUPEX – 2022 IPO with technology-specific listing on the horizon Stem cell specialist Miracell Co., Ltd. (CEO Shin Hyun-soon) announced on November 4th at a signing ceremony at the 2021 Hwasun International Vaccine Forum that it would invest approximately 3 billion won in the construction of a production plant in the Hwasun Vaccine Industrial Complex, a state-of-the-art medical complex. As a leading company in stem cell therapy and medical devices,this agreement will actively contribute to fostering local talent and expanding employment. Miracell Co., Ltd., which began its medical business in 1986, was launched as a stem cell specialist in 2009.Leveraging its decades of expertise, Miracell is pioneering the popularization of the domestic stem cell market with its next-generation bio-regenerative medical device, the “Smart M-cell 2.” “Smart Mcell 2” is a cutting-edge cell extraction system capable of selectively isolating and extracting large quantities of stem cells, which exist in small quantities and are difficult to isolate. If cells collide or become activated during separation, they will be considered dead even when injected into the body. Therefore, the most crucial technology is to extract live, fresh cells. “Smart Mcell 2” met these stringent requirements, receiving NET New Health Technology certification from the Ministry of Health and Welfare and approval from the Ministry of Food and Drug Safety in February 2021. At Seoul National University Bundang Hospital, a performance comparison test of the Smart Mcell 2, a bone marrow and blood stem cell extraction device with a centrifuge capable of selective separation, and the world’s leading product, SmartPrep, showed comparable or superior performance. Miracell’s bio-regenerative medical devices are currently being used across various medical specialties at major hospitals in Korea. Miracell attracted the attention of military officials as the only bio company to participate in the “2021 DUPEX KOREA Asia Defense Exhibition,” held on October 19th.”DUPEX KOREA” is an international event with a 25-year history, attended by high-ranking military and security officials, including Ministers of Defense, Chiefs of Staff, and the Director of the Defense Acquisition Program Administration (DAPA) from over 70 countries. “Smart Mcell 2,” which was selected as an innovative product by the Public Procurement Service, is expected to accelerate the recovery of soldiers from trauma and chronic pain that may occur during training through stem cell therapy,and was highly praised for its potential to contribute to national defense through regenerative medicine. Following its participation in KIMES Seoul, Korea’s largest medical device exhibition, Miracell also participated in KIMES Busan in October, signing contracts with numerous hospitals and clinics, expanding its market share to small cities in the Yeongnam region. Miracell shares stem cell medical technology through a network of hospitals and clinics affiliated with the Cellpia Global Platform (CGP). Over 60 CGP hospitals and clinics are located in Gangnam, Seoul, and other major cities across the country, covering a variety of specialties, including orthopedics, plastic surgery, dermatology, and family medicine. Miracell provides comprehensive services, including education, technology transfer, medical equipment setup, and marketing, to ensure safer stem cell treatments. Ahead of its IPO in 2022, Miracell is actively pursuing its growth and positioning itself as a leader in the bio industry.

Miracell Participates in KIMES Busan with “Smart Mcell 2,” a Cutting-Edge Stem Cell Medical Device

Miracell, a cutting-edge stem cell medical device, will participate in KIMES Busan with its “Smart Mcell 2.” [Edaily Reporter Lee Soon-yong] Stem cell company Miracell (CEO Shin Hyun-soon) participated in the medical device exhibition “KIMES 2021 BUSAN,” held at BEXCO in Busan from the 29th to the 31st of last month. KIMES is Korea’s largest medical device and hospital equipment exhibition. This is the fourth KIMES Busan exhibition,centered around Busan and encompassing Daegu, Ulsan, North Gyeongsang Province, and South Gyeongsang Province. KIMES is an event dedicated to improving public health, advancing medical technology, and revitalizing the local medical and hospital industries. It provides a glimpse into the changing medical industry in response to global trends, attracting approximately 10,000 visitors annually, including medical professionals, industry insiders, buyers, and dealers. Over 180 companies participated in this exhibition, showcasing the latest medical equipment and medical information. Among the over 3,000 cutting-edge medical devices on display,the most notable was Miracell’s “Smart Mcell 2.” Miracell’s “Smart M-cell 2,” a “bone marrow and blood stem cell extraction device with a centrifuge vessel capable of selective separation,” has received approval from the Ministry of Food and Drug Safety and was certified as a new medical technology by the Ministry of Health and Welfare in February 2021. This cutting-edge regenerative medical biodevice extracts large quantities of concentrated, automatically separated stem cells through centrifugation with minimal manipulation, representing the future of K-smart healthcare. With stem cells known to have infinite benefits in cartilage defects, pain management, preventive medicine, and overall healthcare, Miracell’s booth, which showcased the Smart M-cell 2, attracted the attention of numerous medical professionals and healthcare industry professionals. Founded in the medical industry in 1986, Miracell launched in 2009 as a stem cell specialist company. Miracell is leading the popularization of the stem cell market with its Smart Mcell 2, a cutting-edge bio-regenerative medical device developed using proprietary technology, based on accumulated expertise accumulated over many years. In addition to the Seoul metropolitan area, including Gangnam, Miracell has a large number of CGP hospitals and clinics in major cities nationwide, including Daejeon, Daegu, Gwangju, Ulsan, and Busan. These hospitals offer orthopedic, plastic, dermatological, urological, obstetrics and gynecological, and family medicine services. Miracell’s Cellpia Global Platform (CGP) shares stem cell medical technology through a network of member hospitals and clinics. CGP provides education, technology transfer, medical equipment setup, and marketing to ensure safer stem cell regenerative medicine treatments for hospitals both domestically and internationally. Through this KIMES Busan exhibition, Miracell signed contracts with numerous hospitals and clinics, expanding its market share to smaller cities in the Yeongnam region.

Hwasun International Vaccine Forum Opens, Attracting KRW 22.7 Billion in Investment from Pharmaceutical and Healthcare Companies

Hwasun International Vaccine Forum Opens, Attracting KRW 22.7 Billion in Investment from Pharmaceutical and Healthcare Companies Article SummaryInvestment Agreements Signed with Six Companies Specializing in Vaccines, Anticancer Drugs, and MoreHwasun to Be Developed as a Global Vaccine Hub and Bio-Base [Gwangju=Newsis] Reporter Gu Gil-yong = With the 2021 Hwasun International Vaccine Forum opening on the 4th, South Jeolla Province and Hwasun Countysecured 22.7 billion won in investment from six pharmaceutical and healthcare companies. South Jeolla Province and Hwasun County opened the two-day “2021 Hwasun International Vaccine Forum” at the Hanium Culture and Sports Center on the 4th. The forum, themed “The Status of Korean Vaccines in the Era of the COVID-19 Pandemic,” featured both on-site and online presentations. Director General Jerome Kim presented “From Pandemic to Endemic: Lessons Learned from the COVID-19 Outbreak for Global Vaccines.” Further presentations were given by Han-i Kim, CEO of the Light Fund; Professor Jeong Jae-hoon of Gachon University; Professor Kang Chang-yool of Seoul National University; and Seong Baek-rin, Director of the Vaccine Commercialization Technology Development Center. On the 5th, the International Society for Vaccines (ISV) International Conference will be held via video conference. Ahead of the opening of the 2021 Hwasun International Vaccine Forum, Hwasun County, together with South Jeolla Province, signed investment agreements with six domestic companies. The investment company Miracell Co., Ltd. (CEO Shin Hyeon-sun), The total investment is 22.7 billion won, including Brexogen Co., Ltd. (CEO Kim Soo), Jinmatrix Co., Ltd. (CEO Kim Soo-ok), Bioway Co., Ltd. (CEO Kim Jong-woo), Coscience Co., Ltd. (CEO Kim Seong-jun), and BC World Pharmaceutical Co., Ltd. (CEO Hong Seong-han). These companies have decided to invest in the Hwasun Vaccine Industrial Complex, including the construction of production facilities, and to actively foster local talent and expand employment. Bioway, a company specializing in anticancer drug development, will invest 10 billion won; Genematrix, a vaccine developer, will invest 4.5 billion won; Miracell and Brexogen, cell therapy and biopharmaceutical companies, will each invest 3 billion won; BC World Pharmaceutical, a pharmaceutical company, and Coscience, a bio-molecular diagnostics company, will each invest 1.2 billion won and 1 billion won, respectively. Hwasun County has been hosting the Hwasun International Vaccine Forum since 2016, attracting investment from domestic and international pharmaceutical and biotech companies. Furthermore, in March, the company signed a 30 billion won investment memorandum of understanding with Vaxcell Bio (Co-CEOs Lee Jun-haeng and Lee Je-joong). In April, the company also signed a contract to sell a 13,352 square meter factory site in the Hwasun Vaccine Industrial Complex. South Jeolla Province Governor Kim Young-rok emphasized, “We will establish a state-of-the-art medical complex and a large-scale production complex for world-class therapeutic vaccines to make South Jeolla Province a global biomedical hub.” Hwasun County Mayor Koo Chung-gon stated, “For South Korea to leap forward as one of the world’s top five vaccine powerhouses, we must foster Hwasun, Korea’s only vaccine industry special zone, as a true global vaccine hub and bio hub. I will do my best to ensure that Hwasun, a mecca for vaccines and biotechnology, plays a significant role in realizing our goal of becoming one of the top five vaccine powerhouses.” By Koo Gil-yong

Miracell to Exhibit Smart Mcell 2, a Bio-Regenerative Medical Device, at KIMES BUSAN 2021!

Miracell to exhibit Smart Mcell 2, a bio-regenerative medical device, at KIMES BUSAN 2021! Miracell Co., Ltd. (CEO Shin Hyun-soon) will participate in the ‘2021 Busan Medical Equipment Exhibition (KIMES BUSAN 2021)’, held at BEXCO Exhibition Hall 2 in Busan from Friday, October 29th to Sunday, October 31st. Stem cells, known for their remarkable regenerative power and used to treat serious diseases, are undifferentiated cells that regenerate damaged body tissues and transform old, dysfunctional cells into new ones. Miracell Co., Ltd., a stem cell specialist, has developed a bone marrow and blood stem cell extraction device, including a centrifuge vessel capable of selective separation, also known as the ‘Smart M-cell 2’. This bio-regenerative medical device extracts a large amount of stem cells by concentrating bone marrow and blood extracted from the patient’s body through centrifugation with minimal manipulation. Miracell’s “Smart Mcell 2” concentrates hematopoietic stem cells (CD34+) from blood 4-6 times more concentrated than whole blood, and extracts mesenchymal stem cells from bone marrow. Approximately 2.9 billion cells can be isolated and extracted in less than an hour, with a cell viability rate of 94-98%. The closed system prevents air contact, preventing the possibility of deformation. The digital device, equipped with an LED laser, also boasts a sleek exterior design. Miracell CEO Shin Hyun-soon explained, “Stem cells have an exceptional ability to regenerate body tissues, such as blood vessels and skin. Because stem cells are living organisms, preserving not only the number of cells but also the recovery rate and viability is crucial. The success of a treatment depends on the number of living cells injected, and therefore, biological manufacturing technology is crucial.” Miracell actively conducts regular training and support programs for medical professionals to ensure safe and accurate stem cell treatments through the practical transfer of stem cell isolation technology and procedures to CGP hospitals and clinics both domestically and internationally. Meanwhile, KIMES BUSAN 2021, now in its fourth year, is a regionally specialized medical industry exhibition centered around Busan, encompassing Daegu, Ulsan, North Gyeongsang Province, and South Gyeongsang Province. With the consumption and demand for smartphone healthcare content and smart wearable devices rapidly increasing and competition among related companies intensifying, KIMES BUSAN 2021 will provide a venue to exhibit and introduce diverse forms of smart healthcare products and services evolving through big data, the Internet of Things (IoT), biotechnology (BT), and information and communications technology (ICT).

Miracell Co., Ltd. Participates in the 2021 Korea Power Support System Exhibition (DUPEX).

Miracell Co., Ltd. Participates in the 2021 Korea Power Support Systems Exhibition (DUPEX): “Smart Mcell 2 Expected to Provide Stem Cell Treatment for Korean Military Personnel” 【Health Digest | Reporter Choi Min-young】 Stem cell specialist Miracell (CEO Shin Hyun-soon) announced on the 19th that it will participate in the 2021 DUPEX KOREA Asia Defense Exhibition.DUPEX KOREA, held from October 19th to 23rd at the Seoul Airport Special Exhibition Center, is known as an international event with a 25-year history, attended by high-ranking military and security officials, including Ministers of Defense, Chiefs of Staff, and the Director of the Defense Acquisition Program Administration (DAPA), from over 70 countries. This exhibition is co-hosted with the Seoul International Aerospace and Defense Exhibition (ADEX), a mega-event related to defense and security in Asia, to promote the development of military capabilities and the growth of related industries. According to the company, the event will feature the “Smart Mcell 2,” a stem cell treatment bio-device that has been certified as a new health technology by the Ministry of Health and Welfare and an innovative product by the Public Procurement Service. The “Smart M-cell 2,” a bone marrow and blood stem cell extraction device with a centrifuge capable of selective separation, is a regenerative medical device that extracts bone marrow and blood from the body, concentrates them through centrifugation with minimal manipulation, and automatically extracts a large quantity of isolated stem cells.CEO Shin Hyun-soon stated, “Military soldiers who are the mainstay of combat operations, who suffer trauma or chronic pain during training,and hospitalized soldiers, can expect a rapid recovery through stem cell treatment using the ‘Smart M-cell 2.’” “Stem cell regenerative medicine will contribute to national defense while protecting the health of soldiers, and will also help reduce costs by shortening treatment periods.” Meanwhile, at the 2021 DUPEX KOREA, ADEX, a weapons systems exhibition, will showcase aircraft, unmanned aerial vehicles, space systems, ground weapons, support equipment/facilities, and simulators. DUPEX, specializing in force support systems, will exhibit military supplies, including commercialization, vehicles, communication/surveillance equipment, combat support equipment/parts, bulletproof vests, clothing, and food supplies, medical equipment/materials, military facilities, training equipment/materials, and resource management information systems.

Miracell Hosts CGP Academy on “Bone Marrow Stem Cell Extraction Techniques”

Miracell Hosts CGP Academy on “Bone Marrow Stem Cell Extraction Techniques” [Edaily Reporter Lee Soon-yong] Stem cell specialist Miracell (CEO Shin Hyun-soon) announced on the 30th that it held a CGP Academy on the 28th under the theme of “Understanding Pelvic Anatomy and Bone Marrow Stem Cell Extraction Techniques.” Conducted remotely via ZOOM due to COVID-19, the lecture drew significant attention with the participation of Dr. Jeong Chan-il, an orthopedic surgeon and director of Cellpia Clinic, a leading stem cell education medical institution. Following an explanation of pelvic anatomy, the one-hour lecture covered bone marrow collection methods and the resulting differences in outcomes. The video vividly captured the entire process of bone marrow stem cell extraction from an actual patient, with prior consent for filming. The bone marrow stem cells were concentrated and isolated using Miracell’s “SMART M-CELL2” bone marrow stem cell kit, BmSC, which has been certified as a new health technology by the Ministry of Health and Welfare. Smart Mcell 2 is a device system that extracts large quantities of stem cells by concentrating bone marrow blood through centrifugation. It is currently used by major hospitals across various medical specialties. This Miracell CGP Academy lecture, “Bone Marrow Stem Cell Extraction Techniques,” was well-received by participants for sharing core know-how on safely extracting high-quality stem cells and large quantities of viable cells from bone marrow. Dr. Jeong emphasized, “The key is to extract stem cells safely and painlessly using a special trocar from the posterior iliac crest. It is important to insert the instrument while avoiding the iliolumbar ligament and the superior gluteal cutaneous nerve. When performing the procedure in the prone position, it is important to determine whether the ilium is displaced posteroinferiorly or anterosuperiorly,and to check the needle’s internal and external rotational displacement to ensure accurate positioning.” This bone marrow extraction technique training attracted significant interest from doctors at CGP member hospitals and clinics from the very beginning of the application process.Unlike blood, bone marrow extraction requires a high level of technical expertise, and the amount of stem cells that can be extracted varies depending on the extraction method. Since the extraction and injection of large quantities of stem cells is crucial for achieving optimal results, the Q&A session following the lecture encouraged a lively discussion with CGP member physicians. Miracell’s Cellpia Global Platform Academy (CGP) is a platform for sharing stem cell medical technology and knowledge through a network of member hospitals and clinics. Launched in 2019, Miracell Inc.has actively engaged in educational sessions on a variety of topics with hospital and clinic staff to lead the way in specialized stem cell treatment and research and contribute to disease treatment. CGP provides education, technology transfer, medical equipment setup, and marketing services to hospitals and clinics worldwide to ensure safer stem cell regenerative medicine treatments. The GGP membership is a global membership program, integrating both domestic and international stem cell companies. Through technological and academic exchanges, it expands stem cell treatment. Miracell plans to further expand its international exchanges through this non-face-to-face ZOOM Academy.